Burning Rock Biotech (BNR) Receivables - Net (2021 - 2023)

Burning Rock Biotech has reported Receivables - Net over the past 3 years, most recently at $17.6 million for Q4 2023.

  • Quarterly results put Receivables - Net at $17.6 million for Q4 2023, up 13.97% from a year ago — trailing twelve months through Dec 2023 was $17.6 million (up 13.97% YoY), and the annual figure for FY2023 was $17.9 million, up 9.11%.
  • Receivables - Net for Q4 2023 was $17.6 million at Burning Rock Biotech, up from $15.5 million in the prior quarter.
  • Over the last five years, Receivables - Net for BNR hit a ceiling of $17.6 million in Q4 2023 and a floor of $14.4 million in Q4 2021.
  • Median Receivables - Net over the past 3 years was $15.5 million (2022), compared with a mean of $15.8 million.
  • Biggest five-year swings in Receivables - Net: increased 7.21% in 2022 and later grew 13.97% in 2023.
  • Burning Rock Biotech's Receivables - Net stood at $14.4 million in 2021, then rose by 7.21% to $15.5 million in 2022, then grew by 13.97% to $17.6 million in 2023.
  • The last three reported values for Receivables - Net were $17.6 million (Q4 2023), $15.5 million (Q4 2022), and $14.4 million (Q4 2021) per Business Quant data.